{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T11:55:57Z","timestamp":1792756557466,"version":"4.5.0"},"reference-count":356,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T00:00:00Z","timestamp":1592352000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006668","name":"Fondo para la Investigaci\u00f3n Cient\u00edfica y Tecnol\u00f3gica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006668","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016545","name":"Roche Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016545","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Hepatology"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.aohep.2020.06.003","type":"journal-article","created":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T02:09:52Z","timestamp":1593050992000},"page":"546-569","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma"],"prefix":"10.1016","volume":"19","author":[{"given":"Federico","family":"Pi\u00f1ero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Tanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Aballay Soteras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mat\u00edas","family":"Tisi Ba\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melisa","family":"Dirchwolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Fassio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Ruf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Mengarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Borzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezequiel","family":"Ridruejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Descalzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Anders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Mazzolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Reggiardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebasti\u00e1n","family":"Marciano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florencia","family":"Perazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Spina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"McCormack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mart\u00edn","family":"Maraschio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Lagues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adri\u00e1n","family":"Gadano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Villamil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Cairo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Ameigeiras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.aohep.2020.06.003_bib1000","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.aohep.2020.06.003_bib1005","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/bmj.39493.646875.AE","article-title":"Going from evidence to recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.aohep.2020.06.003_bib1010","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S0140-6736(00)04337-3","article-title":"The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials","volume":"357","author":"Moher","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.aohep.2020.06.003_bib1015","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1020","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"Elm von","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.aohep.2020.06.003_bib1025","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1634\/theoncologist.2010-S4-05","article-title":"The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective","volume":"15","author":"Venook","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.aohep.2020.06.003_bib1030","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1001\/jamaoncol.2017.3055","article-title":"The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level","volume":"3","author":"Global Burden of Disease Liver Cancer Collaboration","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1035","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1093\/jnci\/djp288","article-title":"Decreased incidence of hepatocellular carcinoma in hepatitis B vaccines: a 20-year follow-up study","volume":"101","author":"Chang","year":"2009","journal-title":"JNCI J Natl Cancer Inst"},{"key":"10.1016\/j.aohep.2020.06.003_bib1040","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/hep.27388","article-title":"Emerging trends in hepatocellular carcinoma incidence and mortality","volume":"61","author":"Njei","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2020.06.003_bib1045","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1002\/hep.26986","article-title":"Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S.","volume":"59","author":"Wong","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2020.06.003_bib1050","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/hep.28785","article-title":"The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2020.06.003_bib1055","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jhep.2011.05.026","article-title":"The changing scenario of hepatocellular carcinoma over the last two decades in Italy","volume":"56","author":"Santi","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1060","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1007\/s00535-011-0431-9","article-title":"Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease, alcoholic liver disease, and chronic liver disease of unknown etiology: report of the nationwide survey","volume":"46","author":"Tokushige","year":"2011","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1065","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.cld.2015.01.001","article-title":"Global epidemiology of hepatocellular carcinoma","volume":"19","author":"McGlynn","year":"2015","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.aohep.2020.06.003_bib1070","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jhep.2017.03.011","article-title":"Global trends and predictors in hepatocellular carcinoma","volume":"67","author":"Bertuccio","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1075","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1053\/j.gastro.2004.09.011","article-title":"Primary liver cancer: worldwide incidence and trends","volume":"127","author":"Bosch","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.aohep.2020.06.003_bib1080","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1007\/s00535-011-0431-9","article-title":"Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease, alcoholic liver disease, and chronic liver disease of unknown etiology: report of the nationwide survey","volume":"46","author":"Tokushige","year":"2011","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1085","article-title":"Changing trends in etiology- and ethnicity-based annual mortality rates of cirrhosis and hepatocellular carcinoma in the United States","author":"Kim","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2020.06.003_bib1090","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S1665-2681(19)31681-3","article-title":"Etiology of hepatocellular carcinoma in Latin America: a prospective, multicenter, international study","volume":"9","author":"Fassio","year":"2010","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1095","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/liv.13502","article-title":"Hepatocellular carcinoma in South America: evaluation of risk factors, demographics and therapy","volume":"38","author":"Debes","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.aohep.2020.06.003_bib1100","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1590\/S1807-59322010001200010","article-title":"Clinical and epidemiological aspects of hepatocellular carcinoma in Brazil","volume":"65","author":"Carrilho","year":"2010","journal-title":"Clinics"},{"key":"10.1016\/j.aohep.2020.06.003_bib1105","first-page":"47","article-title":"Etiology of hepatocellular carcinoma in Argentina: results of a multicenter retrospective study","volume":"39","author":"Fassio","year":"2009","journal-title":"Acta Gastroenterol Latinoam"},{"key":"10.1016\/j.aohep.2020.06.003_bib1110","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4254\/wjh.v10.i1.41","article-title":"Fatty liver disease, an emerging etiology of hepatocellular carcinoma in Argentina","volume":"10","author":"Pi\u00f1ero","year":"2018","journal-title":"World J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1115","first-page":"1122","article-title":"Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies","volume":"158","author":"Virlogeux","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.aohep.2020.06.003_bib1120","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/hep.28535","article-title":"Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection","volume":"64","author":"El-Serag","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2020.06.003_bib1125","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis","volume":"308","author":"Ganne-Carri\u00e9","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.aohep.2020.06.003_bib1130","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/cld.117","article-title":"Molecular epidemiology of hepatocellular carcinoma","volume":"1","author":"Hoshida","year":"2013","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.aohep.2020.06.003_bib1135","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1053\/j.gastro.2008.09.014","article-title":"Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease","volume":"136","author":"Lok","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.aohep.2020.06.003_bib1140","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1002\/hep.22870","article-title":"Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography","volume":"49","author":"Masuzaki","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2020.06.003_bib1145","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.jhep.2009.01.014","article-title":"Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis","volume":"50","author":"Ripoll","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1150","first-page":"32273","article-title":"HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma","volume":"S0168-8278","author":"Ioannou","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1155","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1053\/j.gastro.2018.07.015","article-title":"Incidence of hepatocellular carcinoma after direct antiviral therapy for HCV in patients with cirrhosis included in surveillance programs","volume":"155","author":"Nahon","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.aohep.2020.06.003_bib1160","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jhep.2018.06.010","article-title":"Impact of DAAs on liver transplantation: major effects on the evolution of in- dications and results. An ELITA study based on the ELTR registry","volume":"69","author":"Belli","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1165","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jhep.2018.03.009","article-title":"Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: a prospective population study","volume":"69","author":"Romano","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1170","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/liv.14041","article-title":"Treatment with direct-acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma","volume":"39","author":"Pi\u00f1ero","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.aohep.2020.06.003_bib1175","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1053\/j.gastro.2010.11.050","article-title":"Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C","volume":"140","author":"Lok","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.aohep.2020.06.003_bib1180","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.aohep.2020.06.003_bib1185","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1053\/j.gastro.2010.01.042","article-title":"Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death","volume":"138","author":"Chen","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.aohep.2020.06.003_bib1190","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/hep.24221","article-title":"Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir","volume":"53","author":"Lee","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2020.06.003_bib1195","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1053\/j.gastro.2012.02.007","article-title":"High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load","volume":"142","author":"Tseng","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.aohep.2020.06.003_bib1200","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1093\/jnci\/djn243","article-title":"Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma","volume":"100","author":"Yang","year":"2008","journal-title":"JNCI J Natl Cancer Inst"},{"key":"10.1016\/j.aohep.2020.06.003_bib1205","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/hep.24121","article-title":"Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan)","volume":"53","author":"Jung","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2020.06.003_bib1210","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S1470-2045(11)70077-8","article-title":"Risk estimation for hepatocellular carcinoma in chronichepatitis B (REACH-B): development and validation of apredictive score","volume":"12","author":"Yang","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1215","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jhep.2015.11.035","article-title":"PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy","volume":"64","author":"Papatheodoridis","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1220","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/hep.29320","article-title":"The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B","volume":"66","author":"Papatheodoridis","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2020.06.003_bib1225","doi-asserted-by":"crossref","DOI":"10.7326\/0003-4819-156-12-201206190-00004","article-title":"Risk for hepatocellular carcinoma in patients with alcoholic cirrhosis: a Danish nationwide cohort study","volume":"156","author":"Jepsen","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.aohep.2020.06.003_bib1230","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/annonc\/mdu020","article-title":"Alcohol and liver cancer: a systematic review and meta-analysis of prospective studies","volume":"25","author":"Turati","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1235","first-page":"1","article-title":"Alcohol intake increases the risk of hepatocellular carcinoma in patients with hepatitis C virus-related compensated cirrhosis: a prospective study","author":"Vandenbulcke","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1240","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.cgh.2010.06.027","article-title":"Obesity and alcohol synergize to increase the risk of incident hepatocellular carcinoma in men","volume":"8","author":"Loomba","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1245","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jhep.2004.10.005","article-title":"Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma","volume":"42","author":"Marrero","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1250","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/hep.28368","article-title":"Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study","volume":"63","author":"Piscaglia","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2020.06.003_bib1255","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.jhep.2010.02.035","article-title":"Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review","volume":"53","author":"Papatheodoridis","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1260","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/apt.12344","article-title":"Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B","volume":"38","author":"Singal","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.aohep.2020.06.003_bib1265","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1136\/gutjnl-2013-306409","article-title":"Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease","volume":"63","author":"Cho","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.aohep.2020.06.003_bib1270","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.jhep.2014.11.031","article-title":"Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: a need for surveillance","volume":"62","author":"Kim","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1275","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.cgh.2012.09.007","article-title":"Annual incidence of hepatocellular carcinoma among patients with alcoholic cirrhosis and identification of risk groups","volume":"11","author":"Mancebo","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1280","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.cgh.2010.06.027","article-title":"Obesity and alcohol synergize to increase the risk of incident hepatocellular carcinoma in men","volume":"8","author":"Loomba","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1285","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/ijc.26165","article-title":"Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies","volume":"130","author":"Wang","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.aohep.2020.06.003_bib1290","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/j.1365-2036.2010.04271.x","article-title":"Systematic review: the association between obesity and hepatocellular carcinoma \u2013 epidemiologic evidence","volume":"31","author":"Saunders","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.aohep.2020.06.003_bib1295","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2020.02.044","article-title":"Disease progression in patients with hepatitis C virus infection treated with direct-acting antiviral agents","author":"Mendizabal","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1300","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.jhep.2004.11.039","article-title":"Coffee consumption reduces the risk of hepatocellular carcinoma independently of its aetiology: a case\u2013control study","volume":"42","author":"Gelatti","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1305","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/CEJ.0000000000000252","article-title":"Coffee and the risk of hepatocellular carcinoma and chronic liver disease","volume":"26","author":"Bravi","year":"2017","journal-title":"Eur J Cancer Prev"},{"key":"10.1016\/j.aohep.2020.06.003_bib1310","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.jhep.2009.07.009","article-title":"Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma","volume":"51","author":"Wu","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0148493","article-title":"Risk factors and post-resection independent predictive score for the recurrence of hepatitis B-related hepatocellular carcinoma","volume":"11","author":"Hung","year":"2016","journal-title":"PLOS ONE"},{"key":"10.1016\/j.aohep.2020.06.003_bib1320","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/SLA.0b013e3182363ff9","article-title":"Long-term results of a randomized, observation-controlled, phase iii trial of adjuvant interferon alfa-2b in hepatocellular carcinoma after curative resection","volume":"255","author":"Chen","year":"2012","journal-title":"Ann Surg"},{"key":"10.1016\/j.aohep.2020.06.003_bib1325","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1001\/2012.jama.11975","article-title":"Association between nucleoside analogues and risk of hepatitis B virus\u2013related hepatocellular carcinoma recurrence following liver resection","volume":"308","author":"Wu","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.aohep.2020.06.003_bib1330","doi-asserted-by":"crossref","first-page":"963","DOI":"10.7326\/0003-4819-134-10-200105150-00010","article-title":"Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial","volume":"134","author":"Kubo","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.aohep.2020.06.003_bib1335","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/hep.21415","article-title":"Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection","volume":"44","author":"Mazzaferro","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2020.06.003_bib1340","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jhep.2016.04.008","article-title":"Unexpected early tumor recurrence in patients with hepatitis C virus-related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution","volume":"65","author":"Reig","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1345","first-page":"1","article-title":"Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals","author":"Conti","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1350","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/hep.29855","article-title":"Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout","volume":"68","author":"Huang","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2020.06.003_bib1355","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/lt.25744","article-title":"Direct-acting antivirals and hepatocellular carcinoma: no evidence of higher waitlist progression or post-transplant recurrence","volume":"26","author":"Pi\u00f1ero","year":"2020","journal-title":"Liver Transplant"},{"key":"10.1016\/j.aohep.2020.06.003_bib1360","first-page":"432","article-title":"Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population","volume":"22","author":"Sherman","year":"1995","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2020.06.003_bib1365","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2018.04.027","article-title":"Compliance with hepatocellular carcinoma surveillance guidelines associated with increased lead-time adjusted survival of patients with compensated viral cirrhosis: a multi-center cohort study","volume":"155","author":"Costentin","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.aohep.2020.06.003_bib1370","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1136\/jms.6.2.108","article-title":"Combined alpha fetoprotein testing and ultrasonography as a screening test for primary liver cancer","volume":"6","author":"Zhang","year":"1999","journal-title":"J Med Screen"},{"key":"10.1016\/j.aohep.2020.06.003_bib1375","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1258\/096914103771773320","article-title":"Screening for liver cancer: results of a randomised controlled trial in Qidong, China","volume":"10","author":"Chen","year":"2003","journal-title":"J Med Screen"},{"key":"10.1016\/j.aohep.2020.06.003_bib1380","first-page":"130","article-title":"Randomized controlled trial of screening for hepatocellular carcinoma","author":"Zhang","year":"2004","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1385","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/(SICI)1097-0142(19960901)78:5<977::AID-CNCR6>3.0.CO;2-9","article-title":"Efficacy of a surveillance program for early detection of hepatocellular carcinoma","volume":"78","author":"Zoli","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.aohep.2020.06.003_bib1390","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/S0168-8278(00)00053-2","article-title":"Serum a-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status","volume":"2001","author":"Trevisani","year":"2001","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1395","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.jhep.2015.06.012","article-title":"Surveillance for hepatocellular carcinoma is associated with increased survival: results from a large cohort in the Netherlands","volume":"63","author":"van Meer","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1400","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1097\/MCG.0000000000000708","article-title":"Hepatocellular carcinoma surveillance among patients with cirrhosis in a population-based integrated health care delivery system","volume":"51","author":"Singal","year":"2017","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1405","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/bjc.2016.422","article-title":"Impact of disease stage and aetiology on survival in hepatocellular carcinoma: implications for surveillance","volume":"116","author":"Johnson","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.aohep.2020.06.003_bib1410","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1111\/apt.14623","article-title":"Intensity of surveillance for hepatocellular carcinoma determines survival in patients at risk in a hepatitis B-endemic area","volume":"47","author":"Kim","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.aohep.2020.06.003_bib1415","first-page":"1","article-title":"Impact of hepatocellular carcinoma etiology and liver function on the benefit of surveillance: a novel approach for the adjustment of lead-time bias","volume":"2018","author":"Toyoda","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.aohep.2020.06.003_bib1420","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1365-2036.2009.04014.x","article-title":"Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis","volume":"30","author":"Singal","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.aohep.2020.06.003_bib1425","doi-asserted-by":"crossref","first-page":"e1001624","DOI":"10.1371\/journal.pmed.1001624","article-title":"Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis","volume":"11","author":"Singal","year":"2014","journal-title":"PLoS Med"},{"key":"10.1016\/j.aohep.2020.06.003_bib1430","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1038\/sj.bjc.6604301","article-title":"Surveillance of cirrhosis for hepatocellular carcinoma: a cost\u2013utility analysis","volume":"98","author":"Thompson Coon","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.aohep.2020.06.003_bib1435","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/j.cgh.2008.08.005","article-title":"Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis","volume":"6","author":"Andersson","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1440","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.jhep.2011.11.022","article-title":"Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer population","volume":"56","author":"Cucchetti","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1445","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/hep.26944","article-title":"Hepatocellular carcinoma screening in patients with compensated hepatitis C virus (HCV)-related cirrhosis aware of their HCV status improves survival: a modeling approach","volume":"59","author":"Mourad","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2020.06.003_bib1450","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jhep.2014.03.037","article-title":"Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma","volume":"61","author":"Cucchetti","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1455","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/apt.13554","article-title":"Years of life that could be saved from prevention of hepatocellular carcinoma","volume":"43","author":"Cucchetti","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.aohep.2020.06.003_bib1460","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1053\/lv.2000.4875","article-title":"Improved survival with screening for hepatocellular carcinoma","volume":"6","author":"Wong","year":"2000","journal-title":"Liver Transplant"},{"key":"10.1016\/j.aohep.2020.06.003_bib1465","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1136\/gut.48.2.251","article-title":"Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis","volume":"48","author":"Bolondi","year":"2001","journal-title":"Gut"},{"key":"10.1016\/j.aohep.2020.06.003_bib1470","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1572-0241.2002.05557.x","article-title":"Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience)","volume":"97","author":"Trevisani","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1475","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jhep.2010.03.010","article-title":"Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival","volume":"53","author":"Santi","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1480","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/ajg.2012.449","article-title":"Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail?","volume":"108","author":"Singal","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1485","series-title":"Factors that affect efficacy of ultrasound surveillance for early","first-page":"1","author":"Del Poggio","year":"2014"},{"key":"10.1016\/j.aohep.2020.06.003_bib1490","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1002\/hep.24545","article-title":"Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities","volume":"54","author":"Trinchet","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2020.06.003_bib1495","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1001\/jamaoncol.2016.3147","article-title":"MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma","volume":"3","author":"Kim","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1500","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/apt.12370","article-title":"Surveillance for hepatocellular cancer with ultrasonography vs. computed tomography \u2013 a randomised study","volume":"38","author":"Pocha","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.aohep.2020.06.003_bib1505","doi-asserted-by":"crossref","first-page":"85","DOI":"10.7326\/0003-4819-154-2-201101180-00006","article-title":"Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States","volume":"154","author":"Davila","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.aohep.2020.06.003_bib1510","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/MEG.0000000000001049","article-title":"Adherence to Barcelona Clinic Liver Cancer therapeutic algorithm for hepatocellular carcinoma in the daily practice","volume":"30","author":"Pi\u00f1ero","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1515","first-page":"493","article-title":"Des-\u03b3-carboxy prothrombin and \u03b1-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma","volume":"138","author":"Lok","year":"2010","journal-title":"Ygast"},{"key":"10.1016\/j.aohep.2020.06.003_bib1520","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1002\/hep.30233","article-title":"Longitudinal assessment of three serum biomarkers to detect very early-stage hepatocellular carcinoma","volume":"69","author":"Choi","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2020.06.003_bib1525","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/j.gastro.2009.04.005","article-title":"Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma","volume":"137","author":"Marrero","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.aohep.2020.06.003_bib1530","first-page":"1","article-title":"Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines","author":"Ayuso","year":"2018","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1535","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1148\/radiol.2017170554","article-title":"Evidence supporting LI-RADS major features for CT- and MR imaging-based diagnosis of hepatocellular carcinoma: a systematic review","volume":"286","author":"Tang","year":"2018","journal-title":"Radiology"},{"key":"10.1016\/j.aohep.2020.06.003_bib1540","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1148\/radiol.12121698","article-title":"New OPTN\/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma","volume":"266","author":"Wald","year":"2013","journal-title":"Radiology"},{"key":"10.1016\/j.aohep.2020.06.003_bib1545","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1148\/radiol.14140690","article-title":"Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging\u2014a systematic review and meta-analysis","volume":"275","author":"Lee","year":"2015","journal-title":"Radiology"},{"key":"10.1016\/j.aohep.2020.06.003_bib1550","doi-asserted-by":"crossref","first-page":"697","DOI":"10.7326\/M14-2509","article-title":"Imaging techniques for the diagnosis of hepatocellular carcinoma","volume":"162","author":"Chou","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.aohep.2020.06.003_bib1555","first-page":"1","article-title":"Comparative 13-year meta-analysis of the sensitivity and positive predictive value of ultrasound, CT, and MRI for detecting hepatocellular carcinoma","author":"Hanna","year":"2015","journal-title":"Abdom Radiol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1560","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1148\/radiol.2501071702","article-title":"Hepatocellular carcinoma with a pseudocapsule on gadolinium-enhanced MR images: correlation with histopathologic findings","volume":"250","author":"Ishigami","year":"2009","journal-title":"Radiology"},{"key":"10.1016\/j.aohep.2020.06.003_bib1565","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/hep.1840380430","article-title":"MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation","volume":"38","author":"Burrel","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2020.06.003_bib1570","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.jhep.2012.01.004","article-title":"Non-invasive diagnosis of hepatocellular carcinoma 62cm in cirrhosis. Diagnostic accuracy assessing fat, capsule and signal intensity at dynamic MRI","volume":"56","author":"Rimola","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1575","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/jgh.13150","volume":"31","author":"Renzulli","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1580","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.ejrad.2008.08.011","article-title":"Small nodules (1\u20132cm) in liver cirrhosis: characterization with contrast-enhanced ultrasound","volume":"72","author":"Jang","year":"2009","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1585","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1053\/j.gastro.2015.02.051","article-title":"Evaluation of early-stage hepatocellular carcinoma by magnetic resonance imaging with gadoxetic acid detects additional lesions and increases overall survival","volume":"148","author":"Kim","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.aohep.2020.06.003_bib1590","first-page":"1","article-title":"Contrast enhanced ultrasound identifies hepatocellular carcinoma in cirrhosis: a large multicenter retrospective study","author":"Terzi","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1595","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1136\/gutjnl-2011-301862","article-title":"Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma","volume":"61","author":"Tremosini","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.aohep.2020.06.003_bib1600","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s12072-007-9038-x","article-title":"Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review","volume":"2","author":"Tateishi","year":"2007","journal-title":"Hepatol Int"},{"key":"10.1016\/j.aohep.2020.06.003_bib1605","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1572-0241.2006.00443.x","article-title":"Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither?","volume":"101","author":"Farinati","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1610","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/1477-7819-11-212","article-title":"Correlation analysis of preoperative serum alpha-fetoprotein (AFP) level and prognosis of hepatocellular carcinoma (HCC) after hepatectomy","volume":"11","author":"Ma","year":"2013","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1615","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1245\/s10434-011-1845-6","article-title":"Hepatic resection for \u201cBCLC Stage A\u201d hepatocellular carcinoma. The prognostic role of alpha-fetoprotein","volume":"19","author":"Santambrogio","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1620","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1007\/s00330-006-0461-5","article-title":"Percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma as a first-line treatment: long-term results and prognostic factors in a large single-institution series","volume":"17","author":"Choi","year":"2006","journal-title":"Eur Radiol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1625","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.crad.2011.10.009","article-title":"Serum alpha-fetoprotein response can predict prognosis in hepatocellular carcinoma patients undergoing radiofrequency ablation therapy","volume":"67","author":"Kao","year":"2012","journal-title":"Clin Radiol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1630","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1148\/radiol.13130940","article-title":"Radiofrequency ablation of hepatocellular carcinoma as first-line treatment: long-term results and prognostic factors in 162 patients with cirrhosis","volume":"270","author":"Lee","year":"2014","journal-title":"Radiology"},{"key":"10.1016\/j.aohep.2020.06.003_bib1635","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1245\/s10434-012-2368-5","article-title":"Prognostic significance of alpha-fetoprotein status in the outcome of hepatocellular carcinoma after treatment of transarterial chemoembolization","volume":"19","author":"Wang","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1640","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/lt.23706","article-title":"Alpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation","volume":"19","author":"Lai","year":"2013","journal-title":"Liver Transplant"},{"key":"10.1016\/j.aohep.2020.06.003_bib1645","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000334454","article-title":"Early decrease in \u03b1-fetoprotein, but not des-\u03b3-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma","volume":"81","author":"Kuzuya","year":"2011","journal-title":"Oncology"},{"key":"10.1016\/j.aohep.2020.06.003_bib1650","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jhep.2012.02.016","article-title":"Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma","volume":"57","author":"Personeni","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1655","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jhep.2017.06.026","article-title":"Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two phase III studies","volume":"67","author":"Bruix","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1660","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S1470-2045(15)00050-9","article-title":"Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial","volume":"16","author":"Zhu","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1665","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.aohep.2020.06.003_bib1670","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1002\/lt.23904","article-title":"Alpha-fetoprotein level >1000ng\/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria","volume":"20","author":"Hameed","year":"2014","journal-title":"Liver Transplant"},{"key":"10.1016\/j.aohep.2020.06.003_bib1675","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2012.05.052","article-title":"Liver transplantation for hepatocellular carcinoma: a model including \u2013 fetoprotein improves the performance of Milan criteria","volume":"143","author":"Duvoux","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.aohep.2020.06.003_bib1680","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1001\/jamaoncol.2016.5116","article-title":"Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) score for hepatocellular carcinoma recurrence after liver transplant","volume":"3","author":"Mehta","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1685","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1053\/j.gastro.2017.09.025","article-title":"Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma","volume":"154","author":"Mazzaferro","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.aohep.2020.06.003_bib1690","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO;2-E","article-title":"Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients","volume":"56","author":"Okuda","year":"1985","journal-title":"Cancer"},{"key":"10.1016\/j.aohep.2020.06.003_bib1695","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0168-8278(99)80173-1","article-title":"A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d\u2019Etude et de Traitement du Carcinome H\u00e9patocellulaire","volume":"31","author":"Chevret","year":"1999","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1700","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/hep.510280322","article-title":"A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators","volume":"28","author":"CLIP TCOTLIP","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2020.06.003_bib1705","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1002\/cncr.10384","article-title":"Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system","volume":"94","author":"Leung","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.aohep.2020.06.003_bib1710","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s005350300038","article-title":"Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score)","volume":"38","author":"Kudo","year":"2003","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1715","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1053\/j.gastro.2014.02.032","article-title":"Development of Hong Kong liver cancer staging system with treatment stratification for patients with hepatocellular carcinoma","volume":"146","author":"Yau","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.aohep.2020.06.003_bib1720","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1055\/s-2007-1007122","article-title":"Prognosis of hepatocellular carcinoma: the BCLC staging classification","volume":"19","author":"Llovet","year":"1999","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.aohep.2020.06.003_bib1725","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/hep.20636","article-title":"Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort","volume":"41","author":"Marrero","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2020.06.003_bib1730","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jhep.2005.12.015","article-title":"Prospective validation of the Barcelona Clinic Liver Cancer staging system","volume":"44","author":"Cillo","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1735","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1572-0241.2007.01604.x","article-title":"Comparison of seven staging systems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response","volume":"103","author":"Guglielmi","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1740","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1002\/hep.25832","article-title":"Resection of hepatocellular cancer \u22642cm: results from two Western centers","volume":"57","author":"Roayaie","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2020.06.003_bib1745","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jhep.2012.11.009","article-title":"Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey","volume":"58","author":"Hasegawa","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1750","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/hep.22648","article-title":"Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies","volume":"49","author":"Cho","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2020.06.003_bib1755","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1002\/lt.20202","article-title":"High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation","volume":"10","author":"Sala","year":"2009","journal-title":"Liver Transplant"},{"key":"10.1016\/j.aohep.2020.06.003_bib1760","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S0016-5085(96)70070-7","article-title":"Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure","volume":"111","author":"Bruix","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1016\/j.aohep.2020.06.003_bib1765","doi-asserted-by":"crossref","DOI":"10.1002\/hep.27431","article-title":"Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis","author":"Berzigotti","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2020.06.003_bib1770","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","article-title":"Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial","volume":"359","author":"Llovet","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.aohep.2020.06.003_bib1775","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","article-title":"Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma","volume":"35","author":"Lo","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2020.06.003_bib1780","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/jhep.2003.50047","article-title":"Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival","volume":"37","author":"Llovet","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2020.06.003_bib1785","first-page":"1","article-title":"Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: additional analyses from phase III RESORCE trial","author":"Finn","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1790","doi-asserted-by":"crossref","first-page":"S100","DOI":"10.1016\/j.jhep.2004.11.015","article-title":"Assessment of the prognosis of cirrhosis: Child\u2013Pugh versus MELD","volume":"42","author":"Durand","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1795","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1055\/s-0034-1394143","article-title":"Systemic therapy for hepatocellular carcinoma: the issue of treatment stage migration and registration of progression using the BCLC-refined RECIST","volume":"34","author":"Reig","year":"2014","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.aohep.2020.06.003_bib1800","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1055\/s-0032-1329906","article-title":"Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: proposal for a subclassification to facilitate treatment decisions","volume":"32","author":"Bolondi","year":"2013","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.aohep.2020.06.003_bib1805","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2014.08.035","article-title":"Usefulness of the HKLC vs. the BCLC staging system in a European HCC cohort","volume":"62","author":"Adhoute","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1810","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000452846","article-title":"Albumin-bilirubin (ALBI) grade as part of the evidence-based clinical practice guideline for HCC of the Japan Society of Hepatology: a comparison with the liver damage and child-pugh classifications","volume":"6","author":"Hiraoka","year":"2017","journal-title":"Liver Cancer"},{"key":"10.1016\/j.aohep.2020.06.003_bib1815","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.dld.2014.02.012","article-title":"Adherence to AASLD guidelines for the treatment of hepatocellular carcinoma in clinical practice: experience of the Bologna Liver Oncology Group","volume":"46","author":"Leoni","year":"2014","journal-title":"Digest Liver Dis"},{"key":"10.1016\/j.aohep.2020.06.003_bib1820","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/hpb.12280","article-title":"Determinants and outcomes of adherence to recommendations from a multidisciplinary tumour conference for hepatocellular carcinoma","volume":"16","author":"Gashin","year":"2014","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.aohep.2020.06.003_bib1825","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1111\/liv.13107","article-title":"The recommended treatment algorithms of the BCLC and HKLC staging systems: does following these always improve survival rates for HCC patients?","volume":"36","author":"Kim","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.aohep.2020.06.003_bib1830","first-page":"1","article-title":"HKLC triages more hepatocellular carcinoma patients to curative therapies compared to BCLC and is associated with better survival","author":"Wallace","year":"2017","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.aohep.2020.06.003_bib1835","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/jgh.14013","article-title":"Adherence to Barcelona Clinic Liver Cancer guidelines in field practice: results of Progetto Epatocarcinoma Campania","volume":"33","author":"Guarino","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1840","doi-asserted-by":"crossref","first-page":"454","DOI":"10.6061\/clinics\/2017(08)01","article-title":"Adherence to BCLC recommendations for the treatment of hepatocellular carcinoma: impact on survival according to stage","volume":"72","author":"Kikuchi","year":"2017","journal-title":"Clinics"},{"key":"10.1016\/j.aohep.2020.06.003_bib1845","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1148\/radiol.2343040350","article-title":"Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation","volume":"234","author":"Lencioni","year":"2005","journal-title":"Radiology"},{"key":"10.1016\/j.aohep.2020.06.003_bib1850","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1007\/s00330-006-0461-5","article-title":"Percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma as a first-line treatment: long-term results and prognostic factors in a large single-institution series","volume":"17","author":"Choi","year":"2006","journal-title":"Eur Radiol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1855","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/ajg.2008.80","article-title":"Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials","volume":"104","author":"Orlando","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1860","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jhep.2009.12.004","article-title":"Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis","volume":"52","author":"Germani","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1865","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1148\/radiol.2016151243","article-title":"Long-term therapeutic outcomes of radiofrequency ablation for subcapsular versus nonsubcapsular hepatocellular carcinoma: a propensity score matched study","volume":"280","author":"Kang","year":"2016","journal-title":"Radiology"},{"key":"10.1016\/j.aohep.2020.06.003_bib1870","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3109\/02656736.2015.1127434","article-title":"Microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma: a systematic review and meta-analysis","volume":"32","author":"Facciorusso","year":"2016","journal-title":"Int J Hyperth"},{"key":"10.1016\/j.aohep.2020.06.003_bib1875","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1002\/hep.27548","article-title":"Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma","volume":"61","author":"Wang","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2020.06.003_bib1880","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1148\/radiol.2017161413","article-title":"Safety and efficacy of irreversible electroporation for the treatment of hepatocellular carcinoma not amenable to thermal ablation techniques: a retrospective single-center case series","volume":"284","author":"Sutter","year":"2017","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.aohep.2020.06.003_bib1885","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jhep.2017.02.022","volume":"67","author":"Sapisochin","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1890","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/jso.24661","article-title":"External radiation or ablation for solitary hepatocellular carcinoma: a survival analysis of the SEER database","volume":"116","author":"Berger","year":"2017","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1895","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jamaoncol.2017.2303","article-title":"Individualized adaptive stereotactic body radiotherapy for liver tumors in patients at high risk for liver damage","volume":"4","author":"Feng","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1900","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/hep.27745","article-title":"The role of hepatic resection in the treatment of hepatocellular cancer","volume":"62","author":"Roayaie","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2020.06.003_bib1905","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.jhep.2014.10.037","article-title":"Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study","volume":"62","author":"Vitale","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1910","first-page":"1","article-title":"The role of liver resection in the management of intermediate and advanced stage hepatocellular carcinoma. A systematic review","author":"Glantzounis","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1915","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1002\/hep.510300629","article-title":"Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation","volume":"30","author":"Llovet","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2020.06.003_bib1920","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1053\/j.gastro.2007.05.024","article-title":"Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis","volume":"133","author":"Ripoll","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.aohep.2020.06.003_bib1925","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1097\/SLA.0b013e3181b977a5","article-title":"Is portal hypertension a contraindication to hepatic resection?","volume":"250","author":"Cucchetti","year":"2009","journal-title":"Ann Surg"},{"key":"10.1016\/j.aohep.2020.06.003_bib1930","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/jhbp.124","article-title":"Influence of clinically significant portal hypertension on surgical outcomes and survival following hepatectomy for hepatocellular carcinoma: a systematic review and meta-analysis","volume":"21","author":"Choi","year":"2014","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"10.1016\/j.aohep.2020.06.003_bib1935","first-page":"1","article-title":"Impact of clinically significant portal hypertension on outcomes after partial hepatectomy for hepatocellular carcinoma: a systematic review and meta-analysis","author":"Liu","year":"2018","journal-title":"Int Hepato-Pancreato-Biliary Assoc"},{"key":"10.1016\/j.aohep.2020.06.003_bib1940","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jhep.2015.08.025","article-title":"Hepatic venous pressure gradient in the preoperative assessment of patients with resectable hepatocellular carcinoma","volume":"64","author":"Cucchetti","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1945","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","article-title":"Expanding consensus in portal hypertension","volume":"63","author":"de Franchis","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1950","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/hep.26700","article-title":"Indocyanine green retention test as a noninvasive marker of portal hypertension and esophageal varices in compensated liver cirrhosis","volume":"59","author":"Lisotti","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2020.06.003_bib1955","doi-asserted-by":"crossref","first-page":"8274","DOI":"10.3748\/wjg.v20.i25.8274","article-title":"Laparoscopic vs open approach to resection of hepatocellular carcinoma in patients with known cirrhosis: systematic review and meta-analysis","volume":"20","author":"Twaij","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.aohep.2020.06.003_bib1960","article-title":"Benefits of laparoscopic liver resection in patients with hepatocellular carcinoma and portal hypertension: a case-matched study","author":"Molina","year":"2017","journal-title":"Surg Endosc"},{"key":"10.1016\/j.aohep.2020.06.003_bib1965","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.surg.2007.12.003","article-title":"Comparison of the outcomes between an anatomical subsegmentectomy and a non-anatomical minor hepatectomy for single hepatocellular carcinomas based on a Japanese nationwide survey","volume":"143","author":"Eguchi","year":"2008","journal-title":"Surgery"},{"key":"10.1016\/j.aohep.2020.06.003_bib1980","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/01.sla.0000201480.65519.b8","article-title":"A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma","volume":"243","author":"Chen","year":"2006","journal-title":"Ann Surg"},{"key":"10.1016\/j.aohep.2020.06.003_bib1985","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1097\/SLA.0000000000001178","article-title":"Surgical resection versus radiofrequency ablation for single hepatocellular carcinoma \u22642cm in a propensity score model","volume":"263","author":"Liu","year":"2016","journal-title":"Ann Surg"},{"key":"10.1016\/j.aohep.2020.06.003_bib1990","first-page":"494a","article-title":"Management of people with early- or very early-stage hepatocellular carcinoma","volume":"44","author":"Majumdar","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.aohep.2020.06.003_bib1995","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jhep.2013.04.009","article-title":"Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellularcarcinoma","volume":"59","author":"Cucchetti","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2000","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.jhep.2012.05.007","article-title":"A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma","volume":"57","author":"Feng","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2005","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1007\/s11605-014-2546-9","article-title":"Surgical resection is better than transarterial chemoembolization for hepatocellular carcinoma beyond Milan criteria independent of performance status","volume":"18","author":"Liu","year":"2014","journal-title":"J Gastrointest Surg"},{"key":"10.1016\/j.aohep.2020.06.003_bib2015","first-page":"1","article-title":"Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan criteria: a RCT","author":"Yin","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2020","first-page":"1515","article-title":"Comparison between different D-Dimer cutoff values to assess the individual risk of recurrent venous thromboembolism: analysis of results obtained in the DULCIS study","volume":"38","author":"Costentin","year":"2015","journal-title":"Int J Lab Hem"},{"key":"10.1016\/j.aohep.2020.06.003_bib2025","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1477-7819-8-55","article-title":"Repeat hepatectomy for recurrent hepatocellular carcinoma: a local experience and a systematic review","volume":"8","author":"Zhou","year":"2010","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2030","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/lt.23919","article-title":"Time of hepatocellular carcinoma recurrence after liver resection and alpha-fetoprotein are important prognostic factors for salvage liver transplantation","volume":"20","author":"Lee","year":"2014","journal-title":"Liver Transplant"},{"key":"10.1016\/j.aohep.2020.06.003_bib2035","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/hep.28339","article-title":"Prospective validation of ab initio liver transplantation in hepatocellular carcinoma upon detection of risk factors for recurrence after resection","volume":"63","author":"F\u00e0brega","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2020.06.003_bib2040","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1053\/j.gastro.2011.02.006","article-title":"Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma","volume":"140","author":"Villanueva","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.aohep.2020.06.003_bib2045","first-page":"1","article-title":"Survival following redo hepatectomy vs radiofrequency ablation for recurrent hepatocellular carcinoma: a systematic review and meta-analysis","author":"Gavriilidis","year":"2016","journal-title":"Int Hepato-Pancreato-Biliary Assoc"},{"key":"10.1016\/j.aohep.2020.06.003_bib2050","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/lt.23605","article-title":"Treatment strategy for recurrent hepatocellular carcinoma: salvage transplantation, repeated resection, or radiofrequency ablation?","volume":"19","author":"Chan","year":"2013","journal-title":"Liver Transplant"},{"key":"10.1016\/j.aohep.2020.06.003_bib2055","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1002\/lt.24952","article-title":"Salvage liver transplantation or repeat hepatectomy for recurrent hepatocellular carcinoma: an intent-to-treat analysis","volume":"23","author":"Lim","year":"2017","journal-title":"Liver Transplant"},{"key":"10.1016\/j.aohep.2020.06.003_bib2060","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/hep.29468","article-title":"Curative salvage liver transplantation in patients with cirrhosis and hepatocellular carcinoma: an intention-to-treat analysis","volume":"67","author":"de Haas","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2020.06.003_bib2065","first-page":"1","article-title":"Liver transplantation is equally effective as a salvage therapy for patients with hepatocellular carcinoma recurrence following radiofrequency ablation or liver resection with curative intent","author":"Muaddi","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2070","first-page":"295","article-title":"Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma","volume":"20","author":"Samuel","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.aohep.2020.06.003_bib2075","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S1470-2045(15)00198-9","article-title":"Articles Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"16","author":"Bruix","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2080","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.jcyt.2018.06.002","article-title":"Effect of dendritic cell-based immunotherapy on hepatocellular carcinoma: a systematic review and meta-analysis","volume":"20","author":"Cong","year":"2018","journal-title":"Cytotherapy"},{"key":"10.1016\/j.aohep.2020.06.003_bib2085","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.dld.2016.07.010","article-title":"Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma patients after curative resection, a systemic review and meta-analysis","volume":"48","author":"Wang","year":"2016","journal-title":"Digest Liver Dis"},{"key":"10.1016\/j.aohep.2020.06.003_bib2095","first-page":"41","article-title":"Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study","volume":"33","author":"On Behalf of the PRECISION V Investigators","year":"2009","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2100","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/hep.510270617","article-title":"Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution","volume":"27","author":"Bruix","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2020.06.003_bib2105","first-page":"625","article-title":"Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma","volume":"24","author":"Oliveri","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.aohep.2020.06.003_bib2110","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1038\/bjc.2013.85","article-title":"A randomised phase II\/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma","volume":"108","author":"Meyer","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.aohep.2020.06.003_bib2115","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1200\/JCO.2015.64.0821","article-title":"Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone","volume":"34","author":"Brown","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2120","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.jhep.2012.01.008","article-title":"Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design","volume":"56","author":"Burrel","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2125","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jhep.2011.07.012","article-title":"Radioembolization for hepatocellular carcinoma","volume":"56","author":"Sangro","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2130","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1111\/j.1600-6143.2009.02695.x","article-title":"A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization","volume":"9","author":"Lewandowski","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.aohep.2020.06.003_bib2135","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/hep.24451","article-title":"Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation","volume":"54","author":"Sangro","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2020.06.003_bib2140","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1002\/hep.26014","article-title":"Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study","volume":"57","author":"Mazzaferro","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2020.06.003_bib2145","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jhep.2012.09.003","article-title":"Radioembolization for hepatocellular carcinoma with portal vein thrombosis: impact of liver function on systemic treatment options at disease progression","volume":"58","author":"Memon","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2150","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/liv.12637","article-title":"In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization?","volume":"35","author":"Fouly El","year":"2014","journal-title":"Liver Int"},{"key":"10.1016\/j.aohep.2020.06.003_bib2155","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1111\/jgh.12621","article-title":"Survival benefit of radioembolization for inoperable hepatocellular carcinoma using yttrium-90 microspheres","volume":"29","author":"Kwok","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2165","doi-asserted-by":"crossref","first-page":"289","DOI":"10.5582\/bst.2015.01089","article-title":"Transarterial Y90 radioembolization versus chemoembolization for patients with hepatocellular carcinoma: a meta-analysis","volume":"9","author":"Zhang","year":"2015","journal-title":"Bst"},{"key":"10.1016\/j.aohep.2020.06.003_bib2170","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.hpb.2015.07.002","article-title":"A systematic review of contralateral liver lobe hypertrophy after unilobar selective internal radiation therapy with Y90","volume":"18","author":"Teo","year":"2016","journal-title":"Int Hepato-Pancreato-Biliary Assoc"},{"key":"10.1016\/j.aohep.2020.06.003_bib2175","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1111\/liv.12750","article-title":"Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma","volume":"35","author":"Kolligs","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.aohep.2020.06.003_bib2180","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2016.08.029","article-title":"Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma","volume":"151","author":"Salem","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.aohep.2020.06.003_bib2185","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/s00270-014-1012-0","article-title":"Randomized comparison of selective internal radiotherapy (SIRT) versus drug-eluting bead transarterial chemoembolization (DEB-TACE) for the treatment of hepatocellular carcinoma","volume":"38","author":"Pitton","year":"2014","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2190","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/S1470-2045(17)30683-6","article-title":"Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial","volume":"18","author":"Vilgrain","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2195","first-page":"1","article-title":"SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Paci","author":"Chow","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2200","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.aohep.2020.06.003_bib2205","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/liv.12622","article-title":"Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC","volume":"35","author":"Ricke","year":"2014","journal-title":"Liver Int"},{"key":"10.1016\/j.aohep.2020.06.003_bib2210","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/j.1572-0241.2007.01712.x","article-title":"Transcatheter Arterial Chemoembolization (TACE) in Hepatocellular Carcinoma (HCC): the role of angiogenesis and invasiveness","volume":"103","author":"Sergio","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2215","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s00280-014-2568-8","article-title":"TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial","volume":"74","author":"Erhardt","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2220","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1002\/ijc.29126","article-title":"The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial","volume":"136","author":"Chao","year":"2014","journal-title":"Int J Cancer"},{"key":"10.1016\/j.aohep.2020.06.003_bib2225","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.jhep.2016.01.012","article-title":"Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial","volume":"64","author":"Lencioni","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2230","first-page":"1","article-title":"Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients \u2013 a prospective, randomized, double-blind, phase III trial","author":"Hoffmann","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.aohep.2020.06.003_bib2235","article-title":"Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial","author":"Kudo","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.aohep.2020.06.003_bib2240","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1200\/JCO.2011.37.1021","article-title":"Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma","volume":"29","author":"Pawlik","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2245","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jhep.2018.11.029","article-title":"Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: the phase III STAH trial","volume":"70","author":"Park","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2250","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1002\/hep.27290","article-title":"Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized phase III trial","volume":"60","author":"Kudo","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2020.06.003_bib2255","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1148\/radiol.2015142140","article-title":"Hepatocellular carcinoma: a phase II randomized controlled double-blind trial of transarterial chemoembolization in combination with biweekly intravenous administration of bevacizumab or a placebo","volume":"277","author":"Pinter","year":"2015","journal-title":"Radiology"},{"key":"10.1016\/j.aohep.2020.06.003_bib2260","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1002\/cncr.30825","article-title":"A phase 2 study of the efficacy and biomarker on the combination of transarterial chemoembolization and axitinib in the treatment of inoperable hepatocellular carcinoma","volume":"123","author":"Chan","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.aohep.2020.06.003_bib2265","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S2468-1253(18)30078-5","article-title":"Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial","volume":"3","author":"Kudo","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2270","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamaoncol.2019.0250","article-title":"Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion","volume":"5","author":"He","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2275","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jhep.2014.03.023","article-title":"Prospective randomized pilot study of Y90+\/\u2212 sorafenib as bridge to transplantation in hepatocellular carcinoma","volume":"61","author":"Kulik","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2280","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s00534-012-0528-4","article-title":"Factors predicting survival after post-transplant hepatocellular carcinoma recurrence","volume":"20","author":"Toso","year":"2012","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"10.1016\/j.aohep.2020.06.003_bib2285","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/lt.20128","article-title":"Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis","volume":"10","author":"Roayaie","year":"2004","journal-title":"Liver Transplant"},{"key":"10.1016\/j.aohep.2020.06.003_bib2290","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199603143341104","article-title":"Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis","volume":"334","author":"Mazzaferro","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.aohep.2020.06.003_bib2295","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1002\/lt.22365","article-title":"Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience","volume":"17","author":"Mazzaferro","year":"2011","journal-title":"Liver Transplant"},{"key":"10.1016\/j.aohep.2020.06.003_bib2300","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1477-2574.2010.00200.x","article-title":"Model for end-stage liver disease exceptions committee activity in Argentina: does it provide justice and equity among adult patients waiting for a liver transplant?","volume":"12","author":"McCormack","year":"2010","journal-title":"Hpb"},{"key":"10.1016\/j.aohep.2020.06.003_bib2305","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/lt.23665","article-title":"Improved waiting-list outcomes in Argentina after the adoption of a model for end-stage liver disease-based liver allocation policy","volume":"19","author":"Cejas","year":"2013","journal-title":"Liver Transplant"},{"key":"10.1016\/j.aohep.2020.06.003_bib2310","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/MEG.0000000000000551","article-title":"Identifying patients at higher risk of hepatocellular carcinoma recurrence after liver transplantation in a multicenter cohort study from Argentina","volume":"28","author":"Pi\u00f1ero","year":"2016","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2315","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1053\/jhep.2001.24563","article-title":"Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival","volume":"33","author":"Yao","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2020.06.003_bib2320","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1053\/jlts.2002.34923","article-title":"Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list","volume":"8","author":"Yao","year":"2002","journal-title":"Liver Transplant"},{"key":"10.1016\/j.aohep.2020.06.003_bib2325","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/hep.22693","article-title":"Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the scientific registry of transplant recipients database","volume":"49","author":"Toso","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2020.06.003_bib2330","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/lt.23652","article-title":"Serum alpha-fetoprotein level independently predicts posttransplant survival in patients with hepatocellular carcinoma","volume":"19","author":"Berry","year":"2013","journal-title":"Liver Transplant"},{"key":"10.1016\/j.aohep.2020.06.003_bib2335","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1136\/gutjnl-2014-308513","article-title":"Liver transplantation for hepatocellular carcinoma beyond the Milan criteria","volume":"65","author":"Xu","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.aohep.2020.06.003_bib2340","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1002\/hep.28643","article-title":"The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: a prospective validation study","volume":"64","author":"Sapisochin","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2020.06.003_bib2345","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1470-2045(08)70284-5","article-title":"Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis","volume":"10","author":"Mazzaferro","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2350","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1111\/liv.13159","article-title":"Liver transplantation for hepatocellular carcinoma: evaluation of the AFP model in a multicenter cohort from Latin America","volume":"36","author":"Pi\u00f1ero","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.aohep.2020.06.003_bib2355","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jhep.2016.10.038","article-title":"Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC","volume":"66","author":"Notarpaolo","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2360","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1097\/TP.0000000000002136","article-title":"Validation of the \u03b1-fetoprotein model for hepatocellular carcinoma recurrence after transplantation in an Asian Population","volume":"102","author":"Rhu","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.aohep.2020.06.003_bib2365","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/lt.20418","article-title":"Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma","volume":"11","author":"Decaens","year":"2005","journal-title":"Liver Transplant"},{"key":"10.1016\/j.aohep.2020.06.003_bib2370","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1245\/s10434-010-0993-4","article-title":"Response to therapy as a criterion for awarding priority to patients with hepatocellular carcinoma awaiting liver transplantation","volume":"17","author":"Vitale","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2375","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/lt.22397","article-title":"Priority of candidates with hepatocellular carcinoma awaiting liver transplantation can be reduced after successful bridge therapy","volume":"17","author":"Cucchetti","year":"2011","journal-title":"Liver Transplant"},{"key":"10.1016\/j.aohep.2020.06.003_bib2380","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/lt.23902","article-title":"Time to transplantation as a predictor of hepatocellular carcinoma recurrence after liver transplantation","volume":"20","author":"Samoylova","year":"2014","journal-title":"Liver Transplant"},{"key":"10.1016\/j.aohep.2020.06.003_bib2385","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1002\/lt.22391","article-title":"Is the treatment of hepatocellular carcinoma on the waiting list necessary?","volume":"17","author":"Majno","year":"2011","journal-title":"Liver Transplant"},{"key":"10.1016\/j.aohep.2020.06.003_bib2390","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1111\/ajt.12774","article-title":"Waiting time and explant pathology in transplant recipients with hepatocellular carcinoma: a novel study using national data","volume":"14","author":"Bittermann","year":"2014","journal-title":"Am J Transplant"},{"key":"10.1016\/j.aohep.2020.06.003_bib2395","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/lt.23753","article-title":"Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy","volume":"19","author":"Mehta","year":"2013","journal-title":"Liver Transplant"},{"key":"10.1016\/j.aohep.2020.06.003_bib2400","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/lt.20526","article-title":"A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation","volume":"11","author":"Yao","year":"2005","journal-title":"Liver Transplant"},{"key":"10.1016\/j.aohep.2020.06.003_bib2405","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/hep.22412","article-title":"Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis","volume":"48","author":"Yao","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2020.06.003_bib2410","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1111\/j.1600-6143.2008.02409.x","article-title":"Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the milan selection criteria","volume":"8","author":"Ravaioli","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.aohep.2020.06.003_bib2415","doi-asserted-by":"crossref","DOI":"10.1002\/lt.21994","article-title":"Morphologic features of advanced hepatocellular carcinoma as a predictor of downstaging and Liver Transplantation: an intention-to-treat analysis","author":"Barakat","year":"2010","journal-title":"Liver Transplant"},{"key":"10.1016\/j.aohep.2020.06.003_bib2420","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1002\/hep.27752","article-title":"Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria","volume":"61","author":"Yao","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2020.06.003_bib2425","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1053\/jlts.2003.50147","article-title":"A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy","volume":"9","author":"Yao","year":"2003","journal-title":"Liver Transplant"},{"key":"10.1016\/j.aohep.2020.06.003_bib2430","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/lt.24169","article-title":"Downstaging hepatocellular carcinoma: a systematic review and pooled analysis","volume":"21","author":"Parikh","year":"2015","journal-title":"Liver Transplant"},{"key":"10.1016\/j.aohep.2020.06.003_bib2435","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/hep.30570","article-title":"Are there upper limits in tumor burden for down-staging of hepatocellular carcinoma to liver transplant? Analysis of the all-comers protocol","volume":"70","author":"Sinha","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2020.06.003_bib2440","article-title":"National experience on down-staging of hepatocellular carcinoma before liver transplant: influence of tumor burden, AFP, and wait time","author":"Mehta","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2020.06.003_bib2445","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1002\/lt.22335","article-title":"Does a patient qualify for liver transplantation after the down-staging of hepatocellular carcinoma?","volume":"17","author":"Yao","year":"2011","journal-title":"Liver Transplant"},{"key":"10.1016\/j.aohep.2020.06.003_bib2450","doi-asserted-by":"crossref","unstructured":"Radioembolization Results in Longer Time-to-Progression and Reduced Toxicity Compared With Chemoembolization in Patients With Hepatocellular Carcinoma 2011;140:497\u2013507.e2. doi:10.1053\/j.gastro.2010.10.049.","DOI":"10.1053\/j.gastro.2010.10.049"},{"key":"10.1016\/j.aohep.2020.06.003_bib2455","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/hep.21465","article-title":"A randomized controlled trial of licartin for preventing hepatoma recurrence after liver transplantation","volume":"45","author":"Xu","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2020.06.003_bib2460","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000367734","article-title":"Phase I trial of sorafenib following liver transplantation in patients with high-risk hepatocellular carcinoma","volume":"4","author":"Siegel","year":"2015","journal-title":"Liver Cancer"},{"key":"10.1016\/j.aohep.2020.06.003_bib2465","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1177\/000313481408000723","article-title":"Can sorafenib increase survival for recurrent hepatocellular carcinoma after liver transplantation? A pilot study","volume":"80","author":"Alsina","year":"2014","journal-title":"Am Surg"},{"key":"10.1016\/j.aohep.2020.06.003_bib2470","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1097\/01.tp.0000262607.95372.e0","article-title":"De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects","volume":"83","author":"Toso","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.aohep.2020.06.003_bib2475","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1002\/hep.23437","article-title":"Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma","volume":"51","author":"Toso","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2020.06.003_bib2480","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jhep.2013.03.029","article-title":"Integrating sorafenib into an algorithm for the management of post-transplant hepatocellular carcinoma recurrence","volume":"59","author":"Toso","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2485","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/TP.0000000000000965","article-title":"Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label phase 3 trial","volume":"100","author":"Geissler","year":"2017","journal-title":"Transplantation"},{"key":"10.1016\/j.aohep.2020.06.003_bib2490","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1002\/lt.22334","article-title":"Tools for monitoring patients with hepatocellular carcinoma on the waiting list and after liver transplantation","volume":"17","author":"Kneteman","year":"2011","journal-title":"Liver Transplant"},{"key":"10.1016\/j.aohep.2020.06.003_bib2495","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/j.1478-3231.2010.02425.x","article-title":"Impact of tumour differentiation to select patients before liver transplantation for hepatocellular carcinoma","volume":"31","author":"Decaens","year":"2011","journal-title":"Liver Int"},{"key":"10.1016\/j.aohep.2020.06.003_bib2500","doi-asserted-by":"crossref","first-page":"S162","DOI":"10.1002\/lt.22361","article-title":"Treatment of recurrent hepatocellular carcinoma after liver transplantation","volume":"17","author":"Davis","year":"2011","journal-title":"Liver Transplant"},{"key":"10.1016\/j.aohep.2020.06.003_bib2505","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jhep.2013.02.026","article-title":"Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case\u2013control study","volume":"59","author":"Sposito","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2510","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/ctr.12150","article-title":"Safety and efficacy of sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation","volume":"27","author":"Waghray","year":"2013","journal-title":"Clin Transplant"},{"key":"10.1016\/j.aohep.2020.06.003_bib2515","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/j.transproceed.2012.06.046","article-title":"Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation?","volume":"44","author":"Vitale","year":"2012","journal-title":"Transplant Proc"},{"key":"10.1016\/j.aohep.2020.06.003_bib2520","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1111\/j.1432-2277.2012.01540.x","article-title":"High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation","volume":"25","author":"Staufer","year":"2012","journal-title":"Transplant Int"},{"key":"10.1016\/j.aohep.2020.06.003_bib2525","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1111\/ajt.15551","article-title":"Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation","volume":"19","author":"Iavarone","year":"2019","journal-title":"Am J Transplant"},{"key":"10.1016\/j.aohep.2020.06.003_bib2530","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1007\/s10147-015-0796-5","article-title":"First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a preliminary study","volume":"20","author":"Liu","year":"2015","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2535","first-page":"1","article-title":"Sorafenib alone vs. sorafenib plus GEMOX as 1","author":"Assenat","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.aohep.2020.06.003_bib2540","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jhep.2014.03.024","article-title":"FOLFOX-4 vs. doxorubicin for hepatocellular carcinoma: Could a negative result be accepted as positive?","volume":"61","author":"Liccioni","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2545","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2550","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.3748\/wjg.v25.i27.3607","article-title":"Intermediate-advanced hepatocellular carcinoma in Argentina: treatment and survival analysis","volume":"25","author":"Pi\u00f1ero","year":"2019","journal-title":"WJG"},{"key":"10.1016\/j.aohep.2020.06.003_bib2555","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1002\/hep.24644","article-title":"Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy","volume":"54","author":"Iavarone","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2020.06.003_bib2560","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/ijcp.12352","article-title":"GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis","volume":"68","author":"Lencioni","year":"2013","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.aohep.2020.06.003_bib2565","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jhep.2014.03.030","article-title":"Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib","volume":"61","author":"Reig","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2570","first-page":"1","article-title":"Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: the GIDEON study","author":"Marrero","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2575","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1200\/JCO.2012.45.8372","article-title":"Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial","volume":"31","author":"Cheng","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2580","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1200\/JCO.2012.48.4410","article-title":"Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study","volume":"31","author":"Johnson","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2585","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1200\/JCO.2013.53.7746","article-title":"SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma","volume":"33","author":"Zhu","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2590","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1200\/JCO.2013.54.3298","article-title":"Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial","volume":"33","author":"Cainap","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2595","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/hep.28600","article-title":"Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma","volume":"64","author":"Cheng","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2020.06.003_bib2600","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s11523-016-0467-0","article-title":"Phase I\/II randomized trial of sorafenib and bevacizumab as first-line therapy in patients with locally advancedor metastatic hepatocellular carcinoma: north central cancer treatment group trial N0745 (Alliance)","volume":"12","author":"Hubbard","year":"2016","journal-title":"Target Oncol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2605","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in rst-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.aohep.2020.06.003_bib2610","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s00535-016-1263-4","article-title":"Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma","volume":"52","author":"Ikeda","year":"2016","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2615","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"New Eng J Med"},{"key":"10.1016\/j.aohep.2020.06.003_bib2620","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1200\/JCO.2012.47.3009","article-title":"Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study","volume":"31","author":"Llovet","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2625","first-page":"2290","article-title":"Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma","volume":"18","author":"Kang","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2630","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/jama.2014.7189","article-title":"Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib","volume":"312","author":"Zhu","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.aohep.2020.06.003_bib2635","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S1470-2045(18)30146-3","article-title":"Articles Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study","volume":"19","author":"Rimassa","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2640","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.aohep.2020.06.003_bib2645","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased (-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2650","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jhep.2013.02.022","article-title":"A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C","volume":"59","author":"Sangro","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2655","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.aohep.2020.06.003_bib2660","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2665","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1002\/hep.24670","article-title":"Clinical decision making and research in hepatocellular carcinoma: pivotal role of imaging techniques","volume":"54","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2020.06.003_bib2670","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1002\/hep.26586","article-title":"Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design","volume":"58","author":"Reig","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2020.06.003_bib2675","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/hep.27729","article-title":"Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib","volume":"62","author":"Iavarone","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2020.06.003_bib2680","doi-asserted-by":"crossref","first-page":"052","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.aohep.2020.06.003_bib2685","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1002\/hep.26487","article-title":"Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: imaging analysis from a prospective randomized trial of Y90\u00b1sorafenib","volume":"58","author":"Vouche","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2020.06.003_bib2690","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.jhep.2017.01.012","article-title":"Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC","volume":"66","author":"Lencioni","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2695","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.jhep.2014.01.014","article-title":"Clinical significance of the best response during repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma","volume":"60","author":"Choi","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2700","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2013.01.039","article-title":"Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization","volume":"58","author":"Jung","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2705","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1002\/hep.26256","article-title":"The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma","volume":"57","author":"Sieghart","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2020.06.003_bib2710","first-page":"1","article-title":"How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma","author":"Hucke","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2715","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1093\/annonc\/mdt247","article-title":"A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer","volume":"24","author":"Kadalayil","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2720","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1159\/000480256","article-title":"Hepatic function during repeated tace procedures and prognosis after introducing sorafenib in patients with unresectable hepatocellular carcinoma: multicenter analysis","volume":"35","author":"Hiraoka","year":"2017","journal-title":"Dig Dis"},{"key":"10.1016\/j.aohep.2020.06.003_bib2725","series-title":"Common terminology criteria for adverse events (CTCAE)","first-page":"1","author":"National Cancer Institute","year":"2010"},{"key":"10.1016\/j.aohep.2020.06.003_bib2730","first-page":"1","article-title":"Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib","author":"Gonz\u00e1lez","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.aohep.2020.06.003_bib2735","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2740","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jhep.2019.05.014","article-title":"Nivolumab in advanced hepatocellular carcinoma: sorafenib-experienced Asian cohort analysis","volume":"71","author":"Yau","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2745","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/hep.29575","article-title":"Pembrolizumab for metastatic hepatocellular carcinoma following live donor liver transplantation: the silver bullet?","volume":"67","author":"Rammohan","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2020.06.003_bib2750","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jhep.2019.10.021","article-title":"Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma","volume":"72","author":"Sangro","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2755","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.cgh.2014.03.038","article-title":"Building the multidisciplinary team for management of patients with hepatocellular carcinoma","volume":"13","author":"Naugler","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2760","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.cgh.2011.11.008","article-title":"Multidisciplinary management of hepatocellular carcinoma","volume":"10","author":"Guy","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2765","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/13651820802356572","article-title":"Implementation of a multidisciplinary treatment team for hepatocellular cancer at a Veterans Affairs Medical Center improves survival","volume":"10","author":"Chang","year":"2008","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.aohep.2020.06.003_bib2770","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1067\/msy.2001.117106","article-title":"Hepatocellular carcinoma: multimodality management","volume":"130","author":"Christians","year":"2001","journal-title":"Surgery"},{"key":"10.1016\/j.aohep.2020.06.003_bib2775","first-page":"1","article-title":"Consensus and clinical practice guidelines in Latin America: who, where and how","volume":"19","author":"Campollo","year":"2019","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2780","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.aohep.2019.12.002","article-title":"Advancements in genomic medicine and the need for updated regional clinical practice guidelines in the field of hepatology","volume":"19","author":"Panduro","year":"2020","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2785","doi-asserted-by":"crossref","first-page":"541","DOI":"10.5604\/01.3001.0012.0914","article-title":"Occult hepatitis B and other unexplored risk factors for hepatocellular carcinoma in Latin America","volume":"17","author":"Roman","year":"2018","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2790","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/hep.30811","article-title":"Clinical impact of genomic diversity from early to advanced hepatocellular carcinoma","volume":"71","author":"Nault","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2020.06.003_bib2795","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jhep.2019.03.007","article-title":"A comprehensive study of epigenetic alterations in hepatocellular carcinoma identifies potential therapeutic targets","volume":"71","author":"Bayo","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.06.003_bib2800","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1186\/s12885-018-5003-4","article-title":"Preoperative diagnosis and prediction of hepatocellular carcinoma: radiomics analysis based on multi-modal ultrasound images","volume":"18","author":"Yao","year":"2018","journal-title":"BMC Cancer"}],"container-title":["Annals of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268120300636?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268120300636?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:41:56Z","timestamp":1761648116000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1665268120300636"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":356,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S1665268120300636"],"URL":"https:\/\/doi.org\/10.1016\/j.aohep.2020.06.003","relation":{},"ISSN":["1665-2681"],"issn-type":[{"value":"1665-2681","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Annals of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aohep.2020.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Fundaci\u00f3n Cl\u00ednica M\u00e9dica Sur, A.C. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}